Helsinn, the Swiss pharmaceutical group focused on building quality cancer care products, has today returned elsiglutide for the treatment of chemotherapy-induced diarrhea to Zealand, thereby concluding the licence agreement between the companies. Elsiglutide is a novel GLP-2 [...]